Previous close | 1.3500 |
Open | 1.1500 |
Bid | 1.2000 |
Ask | 1.3700 |
Strike | 75.00 |
Expiry date | 2026-01-16 |
Day's range | 1.1500 - 1.3500 |
Contract range | N/A |
Volume | |
Open interest | 1.93k |
A Relative Strength Rating upgrade for Bristol Myers Squibb shows improving technical performance. Will it continue?
Shattuck stock plunges as it discontinues the clinical development of SL-172154 for two blood cancer indications and plans to reduce the workforce by 40%.
Prime Medicine collaborates with Bristol Myers Squibb for the development of T-cell therapies. Shares gain.